Horizon Europe Grants for Monoclonal Antibody Development Against Emerging Viral Infections

The European Commission has announced a funding opportunity under Horizon Europe for the development of monoclonal antibodies to combat viral infections caused by Filo-, Nairo-, Phenui-, Picorna-, and Toga viruses. This call aims to strengthen health security by advancing research and development in antiviral therapies. The application window opens on 29 October 2026, with a submission deadline of 17 February 2027. The initiative under Horizon Europe aims to tackle the burden of infectious diseases by supporting the development of monoclonal antibodies. These antibodies target viruses such as Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, and Chikungunya. By advancing these therapies, the program seeks to enhance preparedness for future epidemics and pandemics. The program provides financial support to develop and test monoclonal antibodies for the specified viruses. It encourages proposals that include in-vitro and in-vivo testing, regulatory engagement, and the production of antibody batches following Good Manufacturing Practices (GMP). Successful projects will contribute to the EU’s leading role in therapeutic research. Eligible applicants include research institutions, start-ups, micro, small, and medium-sized enterprises (SMEs) from EU Member States and Associated Countries. Participation from third countries where the targeted viruses are endemic is encouraged to bolster international collaboration. This funding opportunity is crucial for advancing global health security by developing therapies that can be deployed rapidly in response to viral outbreaks. It aligns with the EU Medical Countermeasures Strategy and enhances collaboration across the research ecosystem. What is the deadline for submission? The deadline is 17 February 2027, 17:00 Brussels time. Who can apply for this funding? Research institutions, SMEs, and enterprises from EU Member States and Associated Countries are eligible. Which viruses are targeted by this call? The call targets Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, and Chikungunya viruses. What are the key components of a proposal? Proposals should include in-vitro and in-vivo testing, ADE risk evaluation, GMP production, and first-in-human clinical studies. Where can I find more information? Visit the EU Funding & Tenders Portal for detailed guidelines and submission templates. Eligible applicants are encouraged to thoroughly review the official guidelines and prepare their proposals in alignment with the stated requirements. Ensure all necessary documentation is complete and submitted by the deadline to take advantage of this crucial funding opportunity.